Offline mode

L-Selectin ELISA

Catalog no.30150496
Regulatory Status
RUO
Kit size
12 x 8
Method
ELISA
Incubation time
1 x 2 h, 1 x 10 min
Standard range
0.4 - 25 ng/mL
Specimen / Volumes
10 µL serum, plasma, cell culture supernatant et al.
Substrate / isotope
TMB 450 nm

L-selectin (Leukocyte-Endothelial Cell Adhesion Molecule-1) belongs to the selectin family of adhesion molecules. Together with ELAM-1 (E-selectin) and GMP-140 (P-selectin) L-selectin mediates the initial interactions of leukocytes with endothelial cells. Selectins guide non-activated polymorphonuclear cells to the areas of inflammation in creating first, loose contacts with the endothelial layer. L-selectin in this aspect mediates rolling of PMN's on endothelial cells. The potential binding partners of L-selectin carry a negative charge, probably a sialic acid and/or sulphate, and may contain mannose and fucose. In addition, L-selectin may also interact with ELAM-1 which is expressed on cytokine-activated endothelial cells. L-selectin is constitutively expressed on most leukocytes (PMN's, monocytes, lymphocyte subsets) in a seemingly functional form. It is required for the binding of lymphocytes to the high endothelial venules of peripheral lymph nodes (and therefore serves as a lymphocyte recirculating receptor) and for the invasion of neutrophils into sites of inflammation. When neutrophils are activated, L-selectin is shed by proteolytic cleveage near the transmembrane span. Lymphocytes and monocytes can also shed L-selectin upon activation although the kinetics are significantly lower. A broad range of activating agents including C5a, fMLP, TNF, GM-CSF, IL-8 are effective in inducing this response. The shed form of L-selectin (sL-selectin) is functionally active and at high concentrations can inhibit leukocyte attachment to endothelium. The main source for sL-selectin in serum seems to be tissue localized leukocytes. Determination of soluble/circulating L-selectin could provide more detailed insights into the pathological modifications during various diseases (allergy, deep venous thrombosis, HIV, insulin-dependent diabetes mellitus, Kawasaki Syndrome, malignant B-cell populations, neonatal bacterial infection, sepsis, surgery). Synonyms: Leukocyte-Endothelial Cell Adhesion Molecule-1, CD62L, LECAM-1, MEL-14 antigen, LAM-1, LEU-8 antigen, TQ1 antigen

For concrete data please consult the Instruction for Use in the download box on the top right side.

Our Product Families

Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.

And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.

All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use. 

All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

Image on background

This is who we are.

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.

Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.

Happy to help.

At Tecan, we are driven to improve people’s lives and health.